Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care

Lucia Taramasso(Ospedale Policlinico San Martino), Matteo Bassetti(University of Udine), Paolo Pelosi(Ospedale Policlinico San Martino), Laura Magnasco(Ospedale Policlinico San Martino), Silvia Dettori(Ospedale Policlinico San Martino), Chiara Dentone(Ospedale di Sanremo), Małgorzata Mikulska(Ospedale Policlinico San Martino), Raffaele D’Angelo(Ospedale Policlinico San Martino), Lorenzo Ball(Ospedale Policlinico San Martino), Daniele Roberto Giacobbe(Ospedale Policlinico San Martino), Antonio Vena(Ospedale Policlinico San Martino), Nicolò Patroniti(University of Milano-Bicocca), Paolo Frisoni(Ospedale Policlinico San Martino), Chiara Robba(Ospedale Policlinico San Martino), Federica Portunato(Ospedale Policlinico San Martino), Federica Briano(University of Genoa), Maurizio Loconte(Ospedale Policlinico San Martino)
European Journal of Internal Medicine
August 30, 2021
10.1016/j.ejim.2021.08.020
Cited by 11

Related Papers

Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
|Clinical Infectious Diseases|2019|2.8k
Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017
|JAMA|2020|1k
Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest
|New England Journal of Medicine|2021|979
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance
|JAMA|2018|761
How to manage Pseudomonas aeruginosa infections
|Drugs in Context|2018|743